Shilpa Medicare Reports Strong Q2 FY27 Results

Consolidated net profit surged to Rs 79.18 crore; quarterly revenue reached Rs 529.12 crore.

Reader Takeaway: Strong top-line growth drives profitability, though subsidiary insolvency and one-time tax reversals require careful operational assessment.

What just happened

Shilpa Medicare Limited delivered a robust financial performance for the quarter ended September 30, 2026. The company’s consolidated revenue from operations climbed to Rs 529.12 crore, a significant increase from the Rs 370.12 crore reported in the same quarter last year. Net profit attributable to owners reached Rs 79.18 crore, nearly doubling from the Rs 44.07 crore recorded in Q2 FY26.

Why this matters

The jump in profitability reflects core operational expansion. However, shareholders should note that these figures incorporate a one-time deferred tax liability reversal of Rs 26.84 crore recognized during the half-year, which boosted the bottom line. Excluding the impact of specific accounting adjustments is essential for gauging the company’s underlying recurring earnings power.

Subsidiary Insolvency

A critical update for investors is the Corporate Insolvency Resolution Process (CIRP) initiated by the NCLT Ahmedabad against the company’s subsidiary, FTF Pharma Private Limited, on September 9, 2026. As a result, Shilpa Medicare ceased consolidation of this entity’s financials from September 9 onwards. The exclusion of FTF Pharma caused the reported consolidated revenue and profit before tax to be lower by Rs 2.78 crore and Rs 3.75 crore, respectively, for the period.

What to track next

Investors should monitor the final outcome of the FTF Pharma insolvency process and its long-term impact on the consolidated balance sheet. Additionally, tracking sustained margins without the support of one-time tax credits will be vital for assessing future growth trajectories.